01 Aug 2024 --- Patients with tobacco use disorder experience a reduced desire to smoke when treated with semaglutide — a glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes and obesity — finds a new study conducted at the Case Western Reserve School of Medicine, US.